Alabama is currently home to 1293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery
NCT05731284
Recruiting
The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse surgery
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pelvic Organ Prolapse
Register for Updates
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT03971409
Recruiting
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
Register for Updates
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
NCT03809351
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cogn... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
07/06/2023
Locations: UAB, Birmingham, Alabama
Conditions: Alzheimer Disease
Register for Updates
Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults
NCT05930470
Recruiting
Thirty (30) adults with limited physical function will be recruited to participate in a double-blind pilot randomized controlled crossover trial in which all participants will receive 12-weeks of twice weekly MMT treatment in the first (Phase 1) or second half (Phase 2) of the study period; during the control period, participants will receive sham treatment and will be blinded to the randomization.
Gender:
All
Ages:
60 years and above
Trial Updated:
07/03/2023
Locations: Auburn University, Auburn, Alabama
Conditions: Frailty
Register for Updates
Determining the Role of Social Reward Learning in Social Anhedonia
NCT05617898
Recruiting
This is a clinical trial study that aims to evaluate the specificity of the relationship between reduced sensitivity to social reward and social anhedonia at both behavioral and neural levels. Individuals who recently experienced their first-episode psychosis will be recruited. Participants will be randomized 1:1 to motivational interviewing or a time- and format-matched control probe. At pre- and post-probe, participants will perform two social reward learning tasks in the scanner. With this de... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
07/03/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Psychosis
Register for Updates
Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)
NCT04080245
Recruiting
As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serves as an early biomarker of long-lived antibody responses after vaccination. In this study the investigators will be providing the LAIV to up to 10 healthy subjects and assaying their immune response... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
07/03/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Influenza, Human
Register for Updates
Interventions to Decrease Financial Toxicity
NCT05939440
Recruiting
Financial distress affects 30-70% of cancer patients and describes the burden that patients experience due to the costs of care (CoC). One reason may be because patients lack the appropriate information on CoC that would help them better plan for and manage their CoC. Therefore, the investigators plan to test a Proactive CoC intervention which includes a discussion with a trained educator on CoC information and a Cost Tracking tool to help patients deal with their CoC.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/30/2023
Locations: O'Neal Comprehensive Cancer Center, Birmingham, Alabama
Conditions: Cancer, Breast, Cancer Colorectal, Cancer, Ovarian, Cervical Cancer, Uterine Cancer, Vulvar Cancer
Register for Updates
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
NCT04362644
Recruiting
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/29/2023
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Gender:
All
Ages:
50 years and above
Trial Updated:
06/29/2023
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama
Conditions: Alzheimer Disease
Register for Updates
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
All
Ages:
Between 0 years and 1 year
Trial Updated:
06/26/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Register for Updates
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
NCT05103904
Recruiting
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/26/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
ARrest RESpiraTory Failure From PNEUMONIA
NCT04193878
Recruiting
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/26/2023
Locations: University of Alabama-Birmingham, Birmingham, Alabama
Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Register for Updates